Dr. Darren Sigal, MD

Dr. Sigal practices at Scripps Clinic in Encinitas, California.

Dr. Sigal's NPI, 1417120080, was assigned on April 3, 2008. Dr. Sigal graduated from David Geffen School of Medicine at UCLA in 2002. Dr. Sigal's California license number on file is A84475.

Dr. Sigal's primary practice is Scripps Clinic, at 326 Santa Fe Dr, Encinitas, CA 92024 in San Diego County. The practice phone is (858) 554-9100.

Dr. Sigal's primary practice is Scripps Clinic in Encinitas, California. Dr. Sigal is also affiliated with Scripps Memorial Hospital Encinitas. The medical group on file is Scripps Clinic Medical Group. Dmand AI also links Dr. Sigal to 3 more hospitals, 2 group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sigal practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Sigal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Sigal is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Sigal's licenses on file in 2 states: California and Illinois.

Dmand AI lists arterial blot clot /embolism, breast cancer, chronic anemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer, lymphoma and prostate cancer among the conditions Dr. Sigal treats.

CMS data shows 288,099 Medicare services from Dr. Sigal across 66 procedure codes in 2024, for 816 Medicare patients. Medicare paid $3,396,446 for them.

CMS counts 816 Medicare patients who saw Dr. Sigal in 2024. The largest group is 65 to 74, with 363 patients. 72% of them have high cholesterol, and 68% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sigal's median patient age at 68, with 56% women.

In 2024, Dr. Sigal wrote 1,205 Medicare Part D claims for 187 patients. 87% of them were for generic drugs. CMS names the drug for 1,054 of them, across 20 drugs with 11 or more claims each, at $309,519 in total drug cost. In 2023, CMS named 977 claims across 15 drugs.

Dr. Sigal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sigal as offering telehealth.

Dmand AI links 28 papers to Dr. Sigal, published from 2008 to 2025. 2019 was the busiest year, with 3. The most frequent topics are Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols and Pancreatic Neoplasms. Dr. Sigal has published most often in J Clin Oncol. Dr. Sigal's most frequent co-authors are Alan Saven, MD, David Jacob Hermel, MD and Munveer S. Bhangoo, MD.

Dmand AI links Dr. Sigal to 11 clinical trials, 4 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Pancreatic Neoplasms, Pancreatic Diseases and Carcinoma, Hepatocellular. Halozyme Therapeutics sponsors the most, 2.

CMS Open Payments shows 1,072 general payments to Dr. Sigal from 65 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Celularity, Inc. paid the most, $81,019. It also lists 1 research payment totaling $341 in 2020.

Dr. Sigal graduated from David Geffen School of Medicine at UCLA in 2002. Dr. Sigal is a member of ASCO.

Dr. Sigal is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.